Evidence map›Paper›PMID 39323338›Full record

ReviewCurrent topics in medicinal chemistry2025

Exploring the Therapeutic Potential of Glycyrrhiza Compounds in Alzheimer's Disease: A Comprehensive Review.

Xiaona Song, Xiaotang Wang, Yao Gao, Guoqiang Xu, Xiaoru Yan, Zhaoyang Chen, Guohua Song

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current topics in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Neuroprotective synergy of curcumin andFrontiers in pharmacology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaona SongDepartment of Basic Medical Sciences, Shanxi Medical University, No. 56, Xinjian South Rd, Taiyuan, 030001, China.
Xiaotang WangDepartment of Basic Medical Sciences, Shanxi Medical University, No. 56, Xinjian South Rd, Taiyuan, 030001, China.
Yao GaoDepartment of Psychiatry, First Hospital/First Clinical Medical College of Shanxi Medical University, No. 85 Jiefang South Rd, Taiyuan, 030001, China.
Guoqiang XuDepartment of Basic Medical Sciences, Shanxi Medical University, No. 56, Xinjian South Rd, Taiyuan, 030001, China.
Xiaoru YanDepartment of Basic Medical Sciences, Shanxi Medical University, No. 56, Xinjian South Rd, Taiyuan, 030001, China.
Zhaoyang ChenDepartment of Basic Medical Sciences, Shanxi Medical University, No. 56, Xinjian South Rd, Taiyuan, 030001, China.
Guohua SongDepartment of Basic Medical Sciences, Shanxi Medical University, No. 56, Xinjian South Rd, Taiyuan, 030001, China.

Funding

73rd batch of China Postdoctoral Science Foundation 2023M732155Basic Research Project of Shanxi Province 202203021212028Central Government's Guide to Local Science and Technology Development Fund YDZJSX2022A060National Natural Science Foundation of China 31970513, 82301725Shanxi Provincial Science and Technology Department, central guide local science and technology development fund project YDZJSX2022B009special found for Science and Technology Innovation Teams of Shanxi Provine 202204051002032Traditional Chinese Medicine Research Project of Shanxi Provincial Health Commission 2023ZYYC2034
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder. Research shows that the development of AD is linked to neuroinflammation, endoplasmic reticulum stress, mitochondrial dysfunction, cell death, and abnormal cholinergic signaling. Glycyrrhiza compounds contain active ingredients and extracts that offer multiple benefits, including targeting various pathways, high efficacy with low toxicity, and long-lasting therapeutic effects. These benefits highlight the significant potential of Glycyrrhiza compounds for preventing and treating AD. This review summarizes recent advancements in Glycyrrhiza compounds for preventing and treating AD. It focuses on their inhibitory effects on key signaling pathways, such as Toll-like receptor 4 (TLR4), nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and cholinergic signaling. This study aims to establish a scientific framework for using Glycyrrhiza compounds in the clinical prevention and treatment of AD and to support the development of new therapeutic interventions.

Indexed as

Alzheimer DiseaseGlycyrrhizaNeuroprotective AgentsPlant ExtractsAnimalsHumansSignal TransductionNeuroprotective AgentsPlant ExtractsAlzheimer's diseaseGlycyrrhiza compoundsMulti-targeted actionNeuroinflammationSignaling pathwaysSignaling pathways.

Identifiers

PMID39323338

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.